Psilocybin’s effects on cognition and creativity: A scoping review

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life

(2023) Guy M. Goodwin et al.   JOURNAL OF AFFECTIVE DISORDERS

The costs and benefits of psychedelics on cognition and mood

(2023) Ceyda Sayalı et al.   NEURON

Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development

(2022) R.C. Van Court et al.   Fungal Biology

The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation

(2022) James J Rucker et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics

(2022) Aviad Hadar et al.   JOURNAL OF PSYCHOACTIVE DRUGS

Increased global integration in the brain after psilocybin therapy for depression

(2022) Richard E. Daws et al.   NATURE MEDICINE

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

(2022) Friederike Holze et al.   NEUROPSYCHOPHARMACOLOGY

Psychedelic Cognition—The Unreached Frontier of Psychedelic Science

(2022) Maria Bălăeţ   Frontiers in Neuroscience

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

(2022) Federico Cavanna et al.   Translational Psychiatry

Psilocybin—Mediated Attenuation of Gamma Band Auditory Steady-State Responses (ASSR) Is Driven by the Intensity of Cognitive and Emotional Domains of Psychedelic Experience

(2022) Vojtěch Viktorin et al.   Journal of Personalized Medicine

A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs

(2022) Marco Solmi et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

The Missing Piece? A Case for Microglia’s Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics

(2022) Jared VanderZwaag et al.   NEUROCHEMICAL RESEARCH

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder

(2022) Michael P. Bogenschutz et al.   JAMA Psychiatry

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial

(2022) Robin von Rotz et al.   EClinicalMedicine

Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches

(2021) Albert Garcia-Romeu et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Self-blinding citizen science to explore psychedelic microdosing

(2021) Balázs Szigeti et al.   eLife

The Therapeutic Potential of Psilocybin

(2021) Henry Lowe et al.   MOLECULES

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Spontaneous and deliberate creative cognition during and after psilocybin exposure

(2021) N. L. Mason et al.   Translational Psychiatry

Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses—A Simultaneous EEG–FMRI Study

(2021) Patricia Duerler et al.   CEREBRAL CORTEX

Blinding and expectancy confounds in psychedelic randomized controlled trials

(2021) Suresh D. Muthukumaraswamy et al.   Expert Review of Clinical Pharmacology

Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials

(2021) Eduardo Ekman Schenberg   Expert Review of Clinical Pharmacology

Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study

(2021) Josephine Marschall et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

(2021) Joseph M. Rootman et al.   Scientific Reports

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder

(2021) Manoj K. Doss et al.   Translational Psychiatry

Self-reported negative outcomes of psilocybin users: A quantitative textual analysis

(2020) Bheatrix Bienemann et al.   PLoS One

Emotions and brain function are altered up to one month after a single high dose of psilocybin

(2020) Frederick S. Barrett et al.   Scientific Reports

Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

(2020) Juan José Fuentes et al.   Frontiers in Psychiatry

Psilocybin: from ancient magic to modern medicine

(2020) David E. Nichols   JOURNAL OF ANTIBIOTICS

Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review

(2020) Kristin Heuschkel et al.   Frontiers in Psychiatry

The Structure of Executive Dysfunction in Depression and Anxiety

(2020) Stacie L. Warren et al.   JOURNAL OF AFFECTIVE DISORDERS

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

(2020) Alan K. Davis et al.   JAMA Psychiatry

A systematic study of microdosing psychedelics

(2019) Vince Polito et al.   PLoS One

Microdosing psychedelics: More questions than answers? An overview and suggestions for future research

(2019) Kim PC Kuypers et al.   JOURNAL OF PSYCHOPHARMACOLOGY

T263. Psilocybin Improves Cognitive Control and Downregulates Parietal Cortex in Treatment-Seeking Smokers

(2018) Michael McKenna et al.   BIOLOGICAL PSYCHIATRY

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

(2018) Matthew W. Johnson et al.   NEUROPHARMACOLOGY

Psychedelics: Where we are now, why we got here, what we must do

(2018) Sean J. Belouin et al.   NEUROPHARMACOLOGY

Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing—study on P300 and mismatch negativity in healthy volunteers

(2018) Anna Bravermanová et al.   PSYCHOPHARMACOLOGY

Psilocybin and MDMA reduce costly punishment in the Ultimatum Game

(2018) Anthony S. Gabay et al.   Scientific Reports

Unifying Theories of Psychedelic Drug Effects

(2018) Link R. Swanson   Frontiers in Pharmacology

PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation

(2018) Andrea C. Tricco et al.   ANNALS OF INTERNAL MEDICINE

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition

(2018) Frederick S. Barrett et al.   PSYCHOPHARMACOLOGY

ACNP 57th Annual Meeting: Poster Session III

(2018)   NEUROPSYCHOPHARMACOLOGY

Classic Psychedelics: An integrative review of epidemiology, mystical experience, brain network function, and therapeutics

(2018) Matthew W. Johnson et al.   PHARMACOLOGY & THERAPEUTICS

Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting

(2018) Luisa Prochazkova et al.   PSYCHOPHARMACOLOGY

Effect of Psilocybin on Empathy and Moral Decision-Making

(2017) Thomas Pokorny et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Potential Therapeutic Effects of Psilocybin

(2017) Matthew W. Johnson et al.   Neurotherapeutics

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences

(2017) Theresa M. Carbonaro et al.   PSYCHOPHARMACOLOGY

Psilocybin-induced decrease in amygdala-putamen coupling during an event-related face discrimination task

(2016) O. Grimm et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Annual Research Review: On the relations among self-regulation, self-control, executive functioning, effortful control, cognitive control, impulsivity, risk-taking, and inhibition for developmental psychopathology

(2016) Joel T. Nigg   JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY

Microglia across the lifespan: from origin to function in brain development, plasticity and cognition

(2016) Tuan Leng Tay et al.   JOURNAL OF PHYSIOLOGY-LONDON

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

(2016) Roland R Griffiths et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking

(2016) K. P. C. Kuypers et al.   PSYCHOPHARMACOLOGY

Long-term follow-up of psilocybin-facilitated smoking cessation

(2016) Matthew W. Johnson et al.   AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers

(2015) Rainer Kraehenmann et al.   BIOLOGICAL PSYCHIATRY

Psilocybin, psychological distress, and suicidality

(2015) Peter S Hendricks et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

(2015) Michael P Bogenschutz et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Alucinógenos en las culturas precolombinas mesoamericanas

(2015) F.J. Carod-Artal   NEUROLOGIA

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

(2014) Robin L. Carhart-Harris et al.   Frontiers in Human Neuroscience

Spatiotemporal Brain Dynamics of Emotional Face Processing Modulations Induced by the Serotonin 1A/2A Receptor Agonist Psilocybin

(2013) F. Bernasconi et al.   CEREBRAL CORTEX

Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors

(2012) Michael Kometer et al.   BIOLOGICAL PSYCHIATRY

Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin

(2012) R. L. Carhart-Harris et al.   BRITISH JOURNAL OF PSYCHIATRY

Shaping the renaissance of psychedelic research

(2012) Ben Sessa   LANCET

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

(2012) Mark J. Millan et al.   NATURE REVIEWS DRUG DISCOVERY

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

(2012) R. L. Carhart-Harris et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions

(2012) André Schmidt et al.   PSYCHOPHARMACOLOGY

Serotonin and Prefrontal Cortex Function: Neurons, Networks, and Circuits

(2011) M. Victoria Puig et al.   MOLECULAR NEUROBIOLOGY

Mismatch Negativity Encoding of Prediction Errors Predicts S-ketamine-Induced Cognitive Impairments

(2011) André Schmidt et al.   NEUROPSYCHOPHARMACOLOGY

Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers

(2011) Boris B Quednow et al.   NEUROPSYCHOPHARMACOLOGY

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

(2010) Franz X. Vollenweider et al.   NATURE REVIEWS NEUROSCIENCE

Human hallucinogen research: guidelines for safety

(2008) MW Johnson et al.   JOURNAL OF PSYCHOPHARMACOLOGY